The mycobiome-immune axis: The next frontier in pancreatic cancer

Xin Li; Deepak Saxena

doi:10.1016/j.ccell.2022.01.009

The mycobiome-immune axis: The next frontier in pancreatic cancer

Cancer Cell. 2022 Feb 14;40(2):120-122. doi: 10.1016/j.ccell.2022.01.009.

Authors

Xin Li¹, Deepak Saxena²

Affiliations

¹ Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Urology, NYU Grossman School of Medicine, New York, NY 10016, USA.
² Department of Molecular Pathobiology, New York University College of Dentistry, New York, NY 10010, USA; Laura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY 10016, USA; Department of Surgery, NYU Grossman School of Medicine, New York, NY 10016, USA. Electronic address: ds100@nyu.edu.

Abstract

In this issue of Cancer Cell, Aftab et al. identify a pro-inflammatory cytokine, IL-33, that is released as a chemoattractant for type 2 immune cells in response to the intratumoral mycobiome. Depletion of fungi or deletion of IL-33 in cancer cells significantly decreases pancreatic ductal adenocarcinoma (PDAC) tumor progression and increases survival.

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Carcinoma, Pancreatic Ductal* / metabolism
Humans
Mycobiome* / immunology
Pancreatic Neoplasms* / metabolism

Grants and funding

R01 CA206105/CA/NCI NIH HHS/United States